Search alternatives:
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
ng decrease » nn decrease (Expand Search), _ decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
ng decrease » nn decrease (Expand Search), _ decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
341
-
342
-
343
-
344
-
345
-
346
-
347
-
348
Tacrolimus Decreases Albuminuria in Patients with IgA Nephropathy and Normal Blood Pressure: A Double-Blind Randomized Controlled Trial of Efficacy of Tacrolimus on IgA Nephropathy
Published 2013“…We randomly assigned patients either to receive tacrolimus or placebo with stratification by using a renin angiotensin system blocker. …”
-
349
Neural networks classify states which differ in neuronal activity levels using ensembles of neurons that increase/decrease their activity in each state.
Published 2021“…As a result, there is an increase (neurons 51:100) or decrease (neurons 1:50) in activity levels in State B compared to State A. …”
-
350
-
351
-
352
-
353
-
354
-
355
Overexpression of human PGRN mRNA prevents the decrease in axon outgrowth produced by knockdown of zebrafish PGRN.
Published 2013“…C) Quantification of human PGRN protein levels in non-injected and PGRN mRNA injected zebrafish embryos (24hpf) by ELISA confirmed the overexpression of human PGRN protein following PGRN mRNA injection (100 and 250 ng/µl). *Significantly different from non-injected, p<0.043 (post-hoc Wilcoxon Signed Ranks test) following a significant Friedman Test, p = 0.015.…”
-
356
Non-Pneumatic Anti-Shock Garment (NASG), a First-Aid Device to Decrease Maternal Mortality from Obstetric Hemorrhage: A Cluster Randomized Trial
Published 2013“…We hypothesized the NASG group would have a 50% reduction in adverse outcomes.…”
-
357
-
358
-
359
-
360